BeiGene (BGNE) Stock Forecast & Price Target

$176.33 -3.02 (-1.68%)

(As of 04:00 PM ET)

BeiGene - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 8 Analyst Ratings

Sell
0

Hold
2

Buy
6

Based on 8 Wall Street analysts who have issued ratings for BeiGene in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 2 have given a hold rating, and 6 have given a buy rating for BGNE.

Consensus Price Target

$253.69
43.87% Upside

According to the 8 analysts' twelve-month price targets for BeiGene, the average price target is $253.69. The highest price target for BGNE is $345.00, while the lowest price target for BGNE is $152.50. The average price target represents a forecasted upside of 43.87% from the current price of $176.33.

Get the Latest News and Ratings for BGNE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BeiGene and its competitors.

BGNE Analyst Ratings Over Time

Type	Current Forecast 12/17/23 to 12/16/24	1 Month Ago 11/17/23 to 11/16/24	3 Months Ago 9/18/23 to 9/17/24	1 Year Ago 12/17/22 to 12/17/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)	10 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$253.69	$247.07	$233.42	$278.08
Forecasted Upside	43.87% Upside	30.57% Upside	18.18% Upside	51.90% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

BGNE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BGNE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BeiGene Stock vs. The Competition

Type	BeiGene	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	41.45% Upside	29,826.33% Upside	10.64% Upside
News Sentiment Rating	Neutral News See Recent BGNE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/3/2024	Morgan Stanley 3 of 5 stars		Reiterated Rating	Overweight	$300.00	+45.81%
11/13/2024	TD Cowen 5 of 5 stars		Boost Target	Buy ➝ Buy	$254.00 ➝ $260.00	+32.21%
10/22/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$200.00 ➝ $235.00	+7.12%
9/18/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Benjamin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$288.00	+45.82%
8/8/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$269.00 ➝ $288.00	+57.06%
7/9/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$180.00 ➝ $152.50	+5.82%
Vladimir Lenin was right… (Ad) The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier. Including the name of the #1 company to buy.
3/27/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform ➝ Market Perform	$196.00 ➝ $161.00	+4.67%
2/27/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$350.00 ➝ $345.00	+98.62%
9/12/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$259.00	+25.82%
9/11/2023	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$259.00	+23.78%
8/17/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$287.00	+49.22%
6/30/2023	51job Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/30/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/30/2023	3M Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
2/28/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$213.00 ➝ $262.00	+21.28%
1/20/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$236.00 ➝ $300.00	+9.29%
1/11/2023	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$308.00	+20.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:49 PM ET.

Should I Buy BeiGene Stock? BGNE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, December 12, 2024. Please send any questions or comments about these BeiGene pros and cons to contact@marketbeat.com.

BeiGene
Bull Case

Here are some ways that investors could benefit from investing in BeiGene, Ltd.:

Recent revenue growth of 28.2% year-over-year indicates strong demand for BeiGene's oncology products, suggesting a positive trend in the company's market performance.
The current stock price of $206.01 reflects a stable position in the market, with analysts projecting a consensus target price of $253.69, indicating potential for price appreciation.
Analyst upgrades from firms like Citigroup and JPMorgan Chase & Co. suggest confidence in BeiGene's future performance, with price targets set as high as $300.00.
Insider ownership at 7.43% shows that company executives have a vested interest in the success of BeiGene, which can align their goals with those of shareholders.
A low debt-to-equity ratio of 0.05 indicates that BeiGene, Ltd. is not heavily reliant on debt for financing, which can reduce financial risk and enhance stability.

BeiGene
Bear Case

Investors should be bearish about investing in BeiGene, Ltd. for these reasons:

BeiGene reported a negative earnings per share (EPS) of ($1.15), missing consensus estimates, which may raise concerns about profitability and operational efficiency.
The company has a negative net margin of 25.94%, indicating that it is currently spending more than it earns, which could be a red flag for potential investors.
Insider selling of 57,845 shares worth $11,514,300 in the last 90 days may signal a lack of confidence among executives regarding the company's short-term prospects.
With a projected EPS of -5.49 for the current year, analysts expect continued losses, which could deter investors looking for profitable opportunities.
Market volatility, as indicated by a beta of 0.57, suggests that BeiGene's stock may not be as stable as some investors prefer, potentially leading to higher risk in investment.

BGNE Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for BeiGene is $253.69, with a high forecast of $345.00 and a low forecast of $152.50.
: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BGNE shares.
: According to analysts, BeiGene's stock has a predicted upside of 43.87% based on their 12-month stock forecasts.
: BeiGene has been rated by research analysts at JMP Securities, JPMorgan Chase & Co., Morgan Stanley, and TD Cowen in the past 90 days.
: Analysts like BeiGene less than other "medical" companies. The consensus rating score for BeiGene is 2.75 while the average consensus rating score for "medical" companies is 2.81. Learn more on how BGNE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

This page (NASDAQ:BGNE) was last updated on 12/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeiGene (BGNE) Stock Forecast & Price Target